US brand comparison

Mounjaro vs Ozempic

Mounjaro contains tirzepatide. Ozempic contains semaglutide. Compare approved uses, formulations, and self-pay prices.

Mounjaro vs Ozempic: active ingredients, formulations, and manufacturers
Compare	Mounjaro	Ozempic
Active ingredient	TirzepatideGIP/GLP-1	SemaglutideGLP-1
How it is taken	Injection Once weekly	Injection Once weekly Tablet Once daily, on an empty stomach
Manufacturer	Eli Lilly	Novo Nordisk

Direct evidence

What was actually compared

SURPASS-2

Peer-reviewed paper

Ozempic injection vs Mounjaro

Adults with type 2 diabetes inadequately controlled with metformin.

1,879 participants · 40 weeks · Randomized, open-label

Mean HbA1c change (percentage points)

Treatment-regimen analysis, regardless of treatment adherence or rescue therapy.

SURPASS-2: Mean HbA1c change at 40 weeks. Treatment-regimen analysis, regardless of treatment adherence or rescue therapy.
Treatment & dose	Change
Semaglutide (Ozempic)1 mg weekly injection	−1.86 pp
Tirzepatide (Mounjaro)5 mg weekly injection	−2.01 pp
Tirzepatide (Mounjaro)10 mg weekly injection	−2.24 pp
Tirzepatide (Mounjaro)15 mg weekly injection	−2.3 pp

Each tirzepatide dose lowered HbA1c more than semaglutide 1 mg in this trial.

This trial did not compare Ozempic 2 mg or tablets. HbA1c changes are percentage points, not relative percentages or weight-loss results. Study averages do not predict an individual's result.

Read the paper PubMed abstract Sponsor's analysis detailsReviewed Sep 28, 2026

Weight-loss results by formulation

Each result belongs to its named trial and dose. Separate trials have different participants and methods; these figures are not a direct comparison.

Mounjaro vs Ozempic: sourced weight-loss results by formulation
Compare	Mounjaro	Ozempic
Injection evidence	No reviewed weight-loss result for this brand and formulation.	No reviewed weight-loss result for this brand and formulation.
Tablet evidence	No reviewed weight-loss result for this brand and formulation.	No reviewed weight-loss result for this brand and formulation.

Product-specific costs

Entry price and maintenance price

Self-pay quotes, not insurance estimates. Each figure identifies the product, provider, and dose where published.

Mounjaro vs Ozempic: published self-pay prices by formulation
Compare	Mounjaro	Ozempic
Injection prices	Advertised entry price from $499/28 days 28-day supply ≈ $534.64 per 30 days at this quoted rate Checked Oct 20, 2026 Mounjaro single-dose pens LillyDirect (Eli Lilly) · Manufacturer direct self-pay, four weekly pens; published starting rate at each dose Price conditions self-pay, four weekly pens; published starting rate at each dose The self-pay program requires a prescription for an approved use, age 18+, and US or Puerto Rico residence. Purchases cannot be submitted to insurance or counted toward deductibles or out-of-pocket limits. LillyDirect defines a month's supply as four single-dose pens, one a week, so a fill covers 28 days. 28-day supply View offer Published maintenance dose from $499/28 days 28-day supply ≈ $534.64 per 30 days at this quoted rate Checked Oct 20, 2026 At 15 mg Mounjaro single-dose pens LillyDirect (Eli Lilly) · Manufacturer direct Published price at 15 mg Price conditions Published price at 15 mg The self-pay program requires a prescription for an approved use, age 18+, and US or Puerto Rico residence. Purchases cannot be submitted to insurance or counted toward deductibles or out-of-pocket limits. LillyDirect defines a month's supply as four single-dose pens, one a week, so a fill covers 28 days. The same starting rate is published for all six strengths, 2.5-15 mg. Taxes and additional fees may apply. 28-day supply View offer	Advertised entry price $199/fill initially 28-day supply ≈ $213.21 per 30 days at this quoted rate Offer through Dec 31, 2026 Checked Oct 20, 2026 Ozempic pen NovoCare (Novo Nordisk) · Manufacturer direct first two 28-day fills at 0.25 or 0.5 mg for new patients whose prescription is written and received by Dec 31, 2026 Price conditions first two 28-day fills at 0.25 or 0.5 mg for new patients whose prescription is written and received by Dec 31, 2026 After the introductory offer: $349 per monthly fill for 0.25, 0.5, or 1 mg; $499 for 2 mg. NovoCare defines one injection fill as a 28-day supply. Introductory fills must ship by Jan 31, 2027. Eligibility and restrictions apply. 28-day supply View offer Published maintenance dose $499/28 days 28-day supply ≈ $534.64 per 30 days at this quoted rate Checked Oct 20, 2026 At 2 mg Ozempic pen NovoCare (Novo Nordisk) · Manufacturer direct Published price at 2 mg Price conditions Published price at 2 mg After the introductory offer: $349 per monthly fill for 0.25, 0.5, or 1 mg; $499 for 2 mg. NovoCare defines one injection fill as a 28-day supply. Introductory fills must ship by Jan 31, 2027. Eligibility and restrictions apply. 28-day supply View offer
Tablet prices	No reviewed tablet formulation in this brand record.	Advertised entry price $149/30 days 30-day supply $149 per 30 days at this quoted rate Checked Oct 20, 2026 Ozempic tablets NovoCare (Novo Nordisk) · Manufacturer direct self-pay, 1.5 mg dose Price conditions self-pay, 1.5 mg dose A prescription is required. A bottle of 30 tablets costs $149 at 1.5 mg, $199 at 4 mg and $299 at 9 mg. Self-pay purchases are processed outside insurance and do not count toward deductibles or out-of-pocket limits. 30-day supply View offer Published maintenance dose $299/30 days 30-day supply $299 per 30 days at this quoted rate Checked Oct 20, 2026 At 9 mg Ozempic tablets NovoCare (Novo Nordisk) · Manufacturer direct Published price at 9 mg Price conditions Published price at 9 mg A prescription is required. A bottle of 30 tablets costs $149 at 1.5 mg, $199 at 4 mg and $299 at 9 mg. Self-pay purchases are processed outside insurance and do not count toward deductibles or out-of-pocket limits. 30 tablets per bottle. The 4 mg strength costs $199 per 30-day fill; 9 mg costs $299. 30-day supply View offer

All 4 Mounjaro offers All 6 Ozempic offers

How these quotes are selected

For each price basis, we prefer a recently checked manufacturer-direct quote, then a recently checked provider quote for that brand and formulation. Within each group, documented 30-day costs come first, lowest to highest. Quotes without a documented supply period have no cost rank. Older quotes appear as dated references only when no current quote is tracked. Providers may differ between entry and maintenance prices. Missing maintenance prices are never replaced with entry prices. Compounded products, combined brand quotes, and membership-only fees are excluded. Prices at different doses are not equivalent treatment costs; confirm supply length, eligibility, and added fees.

Every cash quote was checked on or after Oct 15, 2026. Each quote shows its own check date. A quoted maintenance dose is not a dosing recommendation. Our methodology

US prescribing information

Approved uses by formulation

Eligibility, contraindications, and warnings are in each product's full prescribing information.

Mounjaro vs Ozempic: reviewed approved uses by formulation
Compare	Mounjaro	Ozempic
Injection	Glucose control in adults and children 10+ with type 2 diabetes; cardiovascular risk reduction in adults with type 2 diabetes at high cardiovascular risk. US prescribing information (Mounjaro Injection prescribing information) Reviewed Sep 6, 2026	Adults with type 2 diabetes: glucose control; cardiovascular risk reduction with established cardiovascular disease; kidney and cardiovascular protection with chronic kidney disease. US prescribing information (Ozempic Injection prescribing information) Reviewed Sep 6, 2026
Tablet	No reviewed tablet label in this brand record. Ingredient record	Adults with type 2 diabetes: glucose control and cardiovascular risk reduction in those at high risk. The tablet label does not include the injection's kidney indication. US prescribing information (Ozempic Tablet prescribing information) Reviewed Sep 6, 2026

Full evidence and safety information

Tirzepatide: evidence & safety Semaglutide: evidence & safety

Compare the active ingredients

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.